Lurbinectedin
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ewing Sarcoma
Conditions
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Trial Timeline
Jul 27, 2023 → Jul 30, 2028
NCT ID
NCT05918640About Lurbinectedin
Lurbinectedin is a phase 1/2 stage product being developed by Jazz Pharmaceuticals for Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05918640. Target conditions include Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04291937 | Pre-clinical | Completed |
| NCT06217536 | Phase 1/2 | Withdrawn |
| NCT05918640 | Phase 1/2 | Recruiting |
| NCT05734066 | Phase 1/2 | Recruiting |
| NCT05244239 | Phase 1 | Recruiting |
| NCT05126433 | Phase 2 | Terminated |
Competing Products
14 competing products in Ewing Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Linsitinib | Astellas Pharma | Phase 2 | 52 |
| irinotecan liposome (II) + temozolomide + fluzoparib | Sun Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Irinotecan + Temozolomide | Eli Lilly | Phase 2 | 52 |
| IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) | Eli Lilly | Phase 2 | 52 |
| Xaluritamig | Amgen | Phase 1 | 32 |
| CP-751,871 | Pfizer | Phase 1 | 32 |
| CP-751,871 | Pfizer | Phase 1/2 | 40 |
| Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide | Pfizer | Phase 2 | 51 |
| plerixafor + plerixafor + plerixafor | Sanofi | Phase 1/2 | 40 |
| regorafenib tablet | Bayer | Phase 1 | 30 |
| INCB059872 | Incyte | Phase 1 | 30 |
| Lurbinectedin | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| Cabozantinib | Exelixis | Phase 1 | 30 |
| INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil | Inhibrx Biosciences | Phase 1 | 28 |